EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis

Fuhui Li, Tiejun Qin, Bing Li iD, Shiqiang Qu, Lijuan Pan, Peihong Zhang, Qi Sun, Wenyu Cai iD, Qingyan Gao, Meng Jiao, Junjie Li, Xiaofei Ai und 4 weitere

Leukemia · 2024

DOI: 10.1038/s41375-024-02262-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, 2024. Verfasst von Fuhui Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Mutation, Myelodysplastic-Myeloproliferative Diseases, Phosphoproteins, RNA Splicing Factors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China (National Science Foundation of China).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We investigated data from 180 consecutive patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis (MDS/MPN- SF3B1 -T) who were diagnosed according to the 2022 World Health Organization (WHO) classification of myeloid neoplasms to identify covariates associated with survival. At a median follow-up of 48 months (95% confidence interval [CI] 35–61 months), the median survival was 69 months (95% CI 59–79 months). Patients with bone marrow ring sideroblasts (RS) < 15% had shorter median overall survival (OS) than did those with bone marrow RS ≥ 15% (41 months [95% CI 32–50 months] versus 76 months [95% CI 59–93 months]; P < 0.001). According to the univariable analyses of OS, age ≥ 65 years ( P < 0.001), hemoglobin concentration (Hb) < 80 g/L ( P = 0.090), platelet count (PLT) ≥ 800 × 10E + 9/L ( P = 0.087), bone marrow RS < 15% ( P < 0.001), the Revised International Prognostic Scoring System (IPSS-R) cytogenetic category intermediate/poor/very poor ( P = 0.005), SETBP1 mutation ( P = 0.061) and SRSF2 mutation ( P < 0.001) were associated with poor survival. Based on variables selected from univariable analyses, two separate survival prediction models, a clinical survival model, and a clinical-molecular survival model, were developed using multivariable analyses with the minimum value of the Akaike information criterion (AIC) to specifically predict outcomes in patients with MDS/MPN- SF3B1 -T according to the 2022 WHO classification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutationMyelodysplastic-Myeloproliferative DiseasesPhosphoproteinsRNA Splicing FactorsThrombocytosisAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedFollow-Up StudiesMyelodysplastic SyndromesPrognosisSerine-Arginine Splicing FactorsSurvival RateNuclear ProteinsCarrier Proteins

Substanzen

PhosphoproteinsRNA Splicing FactorsSerine-Arginine Splicing FactorsNuclear ProteinsSF3B1 protein, humanSETBP1 protein, humanCarrier ProteinsSRSF2 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical…
  • MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Hematologic Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
  • Centre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, UK.
  • MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. xuzefeng@ihcams.ac.cn.
  • MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. zjxiao@ihcams.ac.cn.

ORCID-Profile: Bing Li, Wenyu Cai, Zefeng Xu, Zhijian Xiao

Förderung

  • National Natural Science Foundation of China (National Science Foundation of China)

Zitieren

APA

Li, F., Qin, T., Li, B., Qu, S., Pan, L., Zhang, P., Sun, Q., Cai, W., Gao, Q., Jiao, M., Li, J., Ai, X., Ma, J., Gale, R. P., Xu, Z., & Xiao, Z. (2024). Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis. Leukemia. https://doi.org/10.1038/s41375-024-02262-2

Vancouver

Li F, Qin T, Li B, Qu S, Pan L, Zhang P, et al. Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis. Leukemia. 2024. doi:10.1038/s41375-024-02262-2

BibTeX
@article{Li2024,
  author = {Li, Fuhui and Qin, Tiejun and Li, Bing and Qu, Shiqiang and Pan, Lijuan and Zhang, Peihong and Sun, Qi and Cai, Wenyu and Gao, Qingyan and Jiao, Meng and Li, Junjie and Ai, Xiaofei and Ma, Jiao and Gale, Robert Peter and Xu, Zefeng and Xiao, Zhijian},
  title = {Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis},
  journal = {Leukemia},
  year = {2024},
  doi = {10.1038/s41375-024-02262-2}
}
Kostenlos starten →